Cargando…
Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management
AL amyloidosis is characterized by a low-level expansion of an indolent, small plasma cell clone that produces amyloidogenic light chains. Amyloid aggregates or preceding intermediaries cause direct cell damage through their proteotoxicity, and amyloid deposits distort tissue architecture, and, even...
Autores principales: | Fotiou, Despina, Dimopoulos, Meletios Athanasios, Kastritis, Efstathios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430233/ https://www.ncbi.nlm.nih.gov/pubmed/32885146 http://dx.doi.org/10.1097/HS9.0000000000000454 |
Ejemplares similares
-
Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma
por: Fotiou, Despina, et al.
Publicado: (2022) -
Biomarkers in AL Amyloidosis
por: Fotiou, Despina, et al.
Publicado: (2021) -
Monoclonal Gammopathy of Thrombotic Significance
por: Gkalea, Vasiliki, et al.
Publicado: (2023) -
Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
por: Theodorakakou, Foteini, et al.
Publicado: (2021) -
De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment
por: Fotiou, Despina, et al.
Publicado: (2021)